Payment & Shipping Terms:
|CAS:||863127-77-9||Alias:||Dasatinib Monohydrate, Dasatinib Hydrate|
|Apparence:||Almost White Crystalline Powder||Purity:||99.5%|
|Stock:||Enough Stock||Grade:||Pharma Grade|
High Purity Dasatinib monohydrate Antineoplastic Cancer Cure Drug 863127-77-9
Product Name: Dasatinib monohydrate
Synonyms: dasatinib monohydrate;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;Dasatinib(TINIBS);N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate;Dastinib;Bms 35482503;Dasatinib hydrate
Product Categories: Molecular Targeted Antineoplastic;API;SPRYCEL;Anti-cancer&immunity;Inhibitors
Jusheng Packing: 1)Aluminum Foil Bag: 100g, 500g, 1Kg 2)Fiber Drum: 25Kg
Jusheng Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Jusheng Clearance Rate: 100% Custom Pass, Diguised Package and Safe Delivery
Jusheng Delivery Time: 5-14 Working Days, Tracking Number Available
Jusheng Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Jusheng Origin: Hubei Province, China
Jusheng Brand Name: Jusheng Brand
Jusheng Production Capacity: 1000Kg/Month
Dasatinib monohydrate Description
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Mechanism of action :
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
How to proceed order